Cover Image
市場調查報告書

口咽念珠菌病 - 開發中產品分析

Oropharyngeal Candidiasis - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 321913
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
口咽念珠菌病 - 開發中產品分析 Oropharyngeal Candidiasis - Pipeline Review, H2 2015
出版日期: 2015年09月09日 內容資訊: 英文 37 Pages
簡介

口咽念珠菌病是由於念珠菌這個真菌隨機感染造成的。雖然嬰兒也會出現口咽念珠菌病症狀,但AIDS患者等免疫機能衰弱的情況下更常造成嚴重感染。症狀有疼痛、吞嚥困難等。

本報告提供口咽念珠菌病治療藥的開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

口咽念珠菌病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/實驗室

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品

開發中的產品:各企業

調查中的產品:各大學/實驗室

治療藥的開發企業

  • Eisai
  • Onxeo SA

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • E-1210
  • E-1211
  • miconazole
  • Prof-002
  • Recombinant Peptides for Oropharyngeal Candidiasis

最新的開發平台資訊

開發中止的產品

產品開發的里程碑

  • 熱門的新聞和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7159IDB

Summary

Global Markets Direct's, 'Oropharyngeal Candidiasis - Pipeline Review, H2 2015', provides an overview of the Oropharyngeal Candidiasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oropharyngeal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oropharyngeal Candidiasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Oropharyngeal Candidiasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Oropharyngeal Candidiasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Oropharyngeal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Oropharyngeal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Candidiasis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Oropharyngeal Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Oropharyngeal Candidiasis Overview
  • Therapeutics Development
    • Pipeline Products for Oropharyngeal Candidiasis - Overview
    • Pipeline Products for Oropharyngeal Candidiasis - Comparative Analysis
  • Oropharyngeal Candidiasis - Therapeutics under Development by Companies
  • Oropharyngeal Candidiasis - Therapeutics under Investigation by Universities/Institutes
  • Oropharyngeal Candidiasis - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Oropharyngeal Candidiasis - Products under Development by Companies
  • Oropharyngeal Candidiasis - Products under Investigation by Universities/Institutes
  • Oropharyngeal Candidiasis - Companies Involved in Therapeutics Development
    • Eisai Co., Ltd.
    • Onxeo SA
  • Oropharyngeal Candidiasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • E-1210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • E-1211 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • miconazole - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Prof-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Oropharyngeal Candidiasis - Recent Pipeline Updates
  • Oropharyngeal Candidiasis - Discontinued Products
  • Oropharyngeal Candidiasis - Product Development Milestones
    • Featured News & Press Releases
      • Apr 01, 2014: BioAlliance Pharma provides an update on its partnerships for Loramyc/Oravig
      • Mar 12, 2013: Sosei Initiates Phase III Study For SO-1105 For Treatment Of Oropharyngeal Candidiasis
      • Jan 07, 2013: BioAlliance Pharma Announces Launch Of Oravig In US
      • Oct 18, 2012: BioAlliance Pharma Signs Agreement With Shafayab Gostar To Distribute Loramyc In Iran
      • Jul 02, 2012: Sosei Completes Phase I Study Of SO-1105 For Treatment Of Oropharyngeal Candidiasis
      • Mar 08, 2012: Sosei Initiates Phase I Study Of SO-1105 In Japan
      • Sep 07, 2011: BioAlliance Decides To Regain Full US Rights For Oravig
      • May 16, 2011: BioAlliance Pharma's Partner Therabel Launches Loramyc In Germany With Support Of Hikma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Oropharyngeal Candidiasis, H2 2015
  • Number of Products under Development for Oropharyngeal Candidiasis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Oropharyngeal Candidiasis - Pipeline by Eisai Co., Ltd., H2 2015
  • Oropharyngeal Candidiasis - Pipeline by Onxeo SA, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Oropharyngeal Candidiasis Therapeutics - Recent Pipeline Updates, H2 2015
  • Oropharyngeal Candidiasis - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Oropharyngeal Candidiasis, H2 2015
  • Number of Products under Development for Oropharyngeal Candidiasis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top